既往乳房隆突术后乳房切除患者的植入物重建:来自国家多中心植入物乳房重建评估研究的经验
该研究基于英国iBRA研究前瞻性纳入的2108例立即植入物乳房重建患者,其中49例有既往隆乳史。与无隆乳史者相比,隆乳组更年轻(中位45岁 vs 50岁,p=0.01)、体重指数更低(22.8 kg/m2 vs 24.9 kg/m2,p<0.01)、肿瘤更小(15 mm vs 25 mm,p=0.01),两组手术技术无差异,术后3个月并发症相似,18个月BREAST-Q患者报告结局无显著差异,支持该术式的安全性。
要点
- 既往隆乳史患者立即植入物乳房重建的3个月并发症与无隆乳史者相似。
- 两组18个月BREAST-Q患者报告结局无显著差异。
- 隆乳组更年轻、体重指数更低、肿瘤更小,手术技术无差异。
核心结论
- 既往隆乳患者立即植入物乳房重建的临床与患者报告结局与iBRA研究更广泛队列所见一致,支持该术式的安全性。
研究设计与样本
- 前瞻性招募英国乳腺与整形外科单位的立即植入物乳房重建患者,比较有与无既往隆乳者的结局。
- iBRA研究共纳入2108例女性,其中49例有既往隆乳史。
主要发现
- 隆乳组中位年龄45岁 vs 无隆乳组50岁(p=0.01),隆乳组更年轻。
- 隆乳组体重指数22.8 kg/m2 vs 无隆乳组24.9 kg/m2(p<0.01),隆乳组更低。
- 隆乳组肿瘤15 mm vs 无隆乳组25 mm(p=0.01),隆乳组更小。
- 两组手术技术无差异,术后3个月并发症相似。
- 18个月BREAST-Q患者报告结局无显著差异。
临床怎么用
- 原文结论为既往隆乳患者立即植入物乳房重建的结局与更广泛iBRA队列一致,支持该术式的安全性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Breast augmentation is the most commonly performed cosmetic procedure, and increasingly women in this group present with breast cancer or request risk-reducing surgery, but their optimal management is unclear. The authors explored the clinical and patient-reported outcomes of patients undergoing immediate implant-based breast reconstruction following previous augmentation and compared these with outcomes of patients who had not had cosmetic implants in the Implant Breast Reconstruction Evaluation (iBRA) Study. METHODS: Patients undergoing immediate implant-based breast reconstruction were prospectively recruited from breast and plastic surgical units across the United Kingdom. Demographic, operative, and oncologic data, and information regarding complications within 3 postoperative months were collected. Patient-reported outcomes at 18 months were assessed using the BREAST-Q. The clinical and patient-reported outcomes of patients undergoing immediate implant-based breast reconstruction with and without previous breast augmentation were compared. RESULTS: A total of 2108 women were included in the iBRA Study, of whom 49 had undergone a previous augmentation. Women in the augmentation group were younger (median age, 45 years versus 50 years; p = 0.01), had a lower body mass index (22.8 kg/m2 versus 24.9 kg/m2; p < 0.01), and had smaller tumors (15 mm versus 25 mm; p = 0.01) than patients without augmentation. No differences were seen in operative technique between the groups. Complications at 3 months were similar in both groups and there were no significant differences in patient-reported outcomes at 18 months. CONCLUSIONS: The clinical and patient-reported outcomes of patients undergoing immediate implant-based breast reconstruction following previous augmentation are consistent with those observed in the wider iBRA Study cohort, supporting the safety of this approach.
引用
- Baker BG, Sewart E, Harvey J, et al. Implant-Based Reconstruction following Mastectomy in Patients Who Have Had a Previous Breast Augmentation: Lessons from the National Multicenter Implant Breast Reconstruction Evaluation Study. Plast Reconstr Surg. 2022. PMID: 35077406. doi:10.1097/PRS.0000000000008713
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。